Michael Scott Robeson

High Impact

Associate Professor

UAMS

Biomedical Informatics, College of Medicine

2 h-index 7 pubs 5 cited

Research Areas

Biomedical Subjects

Links

ORCID Google Scholar Research Group UAMS TRI Profile

OverviewAI-generated summary

Michael Scott Robeson's research focuses on the analysis and management of microbiome data. He has contributed to the development of QIIME 2, a software platform designed for reproducible, interactive, and scalable microbiome data science. His work includes the creation of RESCRIPt, a tool for reproducible sequence taxonomy reference database management.

Robeson's publications also address the diversity of microbial communities in various environments. This includes studies on soil microbial assemblages, examining bacteria, archaea, fungi, and viruses. He has investigated how factors such as plant hosts and soil origin influence these microbial communities, particularly in the roots of woody plants. Collaborations with researchers at the University of Arkansas for Medical Sciences, including Reza Hakkak, Christopher E. Randolph, David W. Ussery, and Charity L. Washam, have resulted in shared publications in these areas.

Metrics

h-index: 2
Publications: 7
Citations: 5

Positions

Associate Professor 2024–present

University of Arkansas for Medical Sciences Biomedical Informatics, College of Medicine Institutional directory
Assistant Professor 2017–2024

University of Arkansas for Medical Sciences Biomedical Informatics ORCID

Selected Publications

A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence (2026)

Oncotarget DOI OpenAlex
Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs (2026)

Cancer Research DOI OpenAlex
Late-in-life treadmill training mitigates gut microbiome imbalances and cardiovascular disease risk in mice (2026)

American Journal of Physiology-Gastrointestinal and Liver Physiology DOI OpenAlex
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)

medRxiv DOI OpenAlex
Changes in gut, microbiome, and cognition after doxorubicin, cyclophosphamide, and paclitaxel chemotherapy treatment (2026)

Scientific Reports 2 citations DOI OpenAlex
Implications of cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy on hippocampal-dependent cognition and gut microbiome (2025)

Frontiers in Microbiomes 1 citation DOI OpenAlex
The effect of obesity and dietary soy protein with different isoflavone levels on fecal microbial composition in lean and obese Zucker rats over 9- and 18-week periods (2025)

Food & Function 1 citation DOI OpenAlex
Oat bran fiber protects against radiation-induced disruption of gut barrier dynamics and mucosal damage (2025)

npj Biofilms and Microbiomes 4 citations DOI OpenAlex
Obesity and Dietary Soy Protein With Different Isoflavone Levels Alter Fecal Microbial Composition in Zucker Rats Over 9- and 18-Week Periods (2025)

DOI OpenAlex
Fueling the fire: colonocyte metabolism and its effect on the colonic epithelia (2025)

Critical Reviews in Food Science and Nutrition 12 citations DOI OpenAlex
MOSHPIT: accessible, reproducible metagenome data science on the QIIME 2 framework (2025)

bioRxiv (Cold Spring Harbor Laboratory) 10 citations DOI OpenAlex
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida (2025)

medRxiv 3 citations DOI OpenAlex
Gut Microbiome Diversity and Composition Changes Post Allogeneic Hematopoietic Stem Cell Transplant (AlloSCT): A Single-Center Prospective Analysis (2024)

Blood DOI OpenAlex
Dietary soy protein reverses obesity-induced liver steatosis and alters fecal microbial composition independent of isoflavone level (2024)

Frontiers in Nutrition 4 citations DOI OpenAlex
Bioinformatics challenges for profiling the microbiome in cancer: pitfalls and opportunities (2024)

Trends in Microbiology 14 citations DOI OpenAlex

View all publications on OpenAlex →

Research Interests

Dr. Robeson currently focuses on the human microbiome and its relationship to nutrition and cancer therapeutics, while also contributing to the development of bioinformatics tools to aid in these studies. Dr. Robeson’s research interests center on the human cancer microbiome, which is an important and booming area of research and is in line with the current UAMS plan for NCI designation, as it has become increasingly clear that the efficacy of anticancer treatments is not only affected by host genetic and immunological factors but are also substantially mediated by the host microbiome. Microbial community dynamics, disease resistance, human health, and agricultural productivity are all highly affected, or dependent upon, microbes. Dr. Robeson’s research integrates bioinformatics, microbial ecology, and integrative multi-omics technologies, to study host-microbe interactions. Particularly those that affect human health and agricultural productivity.; Microbiome; Microbiome Data Science; Microbial Ecology; Human Microbiome; Bioinformatics; eDNA; Phylogenetics; Cancer Microbiome; Microbiome Science; Metagenomics; Host-microbe Interactions

Grants & Funding

As listed on this researcher's institutional profile.

Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi NCI Co-Investigator
Improvement of cellular immunotherapy during dysbiosis- Resubmission NIH Co-Investigator
Improvement of cellular immunotherapy during dysbiosis NIH/Nat. Cancer Institute Principal Investigator
Regulation of macrophage function during acute infection with Plasmodium NIH Co-Investigator
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal NIH Co-Investigator
Center for Translational Pediatric Research (CTPR) NIH/NIGMS Other Key Personnel
Obstructive Sleep Apnea Arkansas Research Alliance Co-Investigator